Chronic Obstructive Pulmonary Disease With Bronchospasms — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for chronic obstructive pulmonary disease with bronchospasms. 9 active patents protecting 1 drugs from 1+ originators. First major cliff: 2026. Daily refresh.

1
Approved drugs
9
Active US patents
68/100
Avg vulnerability
$2.5B
Annual revenue covered

Originators in Chronic Obstructive Pulmonary Disease With Bronchospasms

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Boehringer Ingelheim 9 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating chronic obstructive pulmonary disease with bronchospasms. Each bar = one year. Y-axis scaled to peak year (3 patents).

2
26
3
27
2
28
1
30
1
31

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Spiriva
TIOTROPIUM BROMIDE
 Boehringer Ingelheim 9 68 $2.5B 2026-07-19

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8022082 Spiriva other 80 2026-07-19
7396341 Spiriva other 80 2027-04-10
9027967 Spiriva other 75 2027-09-30
7837235 Spiriva other 75 2028-09-13
8733341 Spiriva other 68 2031-04-16
7396341 Spiriva formulation 65 2026-10-10
9027967 Spiriva formulation 60 2027-03-31
7837235 Spiriva formulation 60 2028-03-13
8733341 Spiriva formulation 48 2030-10-16

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
8733341 Spiriva formulation 48 2030-10-16
7837235 Spiriva formulation 60 2028-03-13
9027967 Spiriva formulation 60 2027-03-31
7396341 Spiriva formulation 65 2026-10-10
8733341 Spiriva other 68 2031-04-16
7837235 Spiriva other 75 2028-09-13
9027967 Spiriva other 75 2027-09-30
7396341 Spiriva other 80 2027-04-10
8022082 Spiriva other 80 2026-07-19

Related